ALVR - SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AlloVir Inc. of Class Action Lawsuit and Upcoming Deadlines – ALVR | Benzinga
NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR). The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 24-cv-10152, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired AlloVir securities between March 22, 2022 and December 21, 2023, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
If you are a shareholder who purchased or otherwise acquired AlloVir securities during the Class Period, you have until March 19, 2024, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at